Dr. Biggs has worked for over 30 years as an independent Pharma consultant specializing in the registration, development and scale up of solid dosage forms, solutions and drug device combinations including sterile injectables. Projects have been successfully performed for the following clients or for their suppliers including Eli Lilly, Pharmacia, 3M Riker, Nordic Pharma, ING Fertility Inc, Les Laboratoires Brothier, Advantage Dental Inc, Ghimas spa and Dexcel Pharma. He has worked as a consultant to Xechem for three years and obtained orphan drug status for Nicosan within the EU.
Dr. Biggs has served as the CEO of Registration, Reimbursement & Development Consultants-Martin Biggs Associates (MBA) from 1969 to the present. It handles the registration of drugs, devices and drug/device combinations in Europe and the USA, and employs a team of regulatory consultants working with clients from a number of international locations. He has also served as CEO of GBM Authorised Representative Ltd. from 1994 to the present, which acts as an authorized representative service for EU suppliers of medical devices and IVD's. Dr. Biggs is presently also the CEO of Pharma Sol International, Ltd., which is developing two patent protected solutions for the replacement of normal saline and as a wound growth accelerator. Dr. Biggs is a Fellow of the Royal Society of Medicine (UK) and a Member of the British Institute of Regulatory Affairs. He holds a BA (honors) degree as well as a Masters of Science and is a Doctor of Philosophy. Prior employment experience includes serving as a health care product group manager from 1973-9 with Scholl (UK) Ltd., as a product manager for drug and regulatory matters with Sherwood Medical Industries (1972-3), project coordinator with 3M Medical (1972-3) and special projects assistant with British Oxygen Cryogenics (1968-70).
Dr. Biggs has specialized expertise in providing advice in a broad area of health care related areas including: drug tariff registration; reimbursement advice; licensing of products in Europe (ethical pharmaceuticals and OTC); registration of medical devices; reagent registration and reimbursement, small scale efficacy testing; new product development and management; acquisition and licensing arrangements; small scale tabletting, formulation and placebo production; reformulation studies, blow-fill seal technology and sterile injectables. He is an author and speaker on a wide variety of topics and holds three health care related patents issued in the UK.
Market Data 
Markets 
